HIP ATTACK-2 Trial: Accelerated Surgery for Hip Fractures with Myocardial Injury

This study, called HIP ATTACK-2, is looking at whether having hip fracture surgery sooner can help patients who also have a heart muscle injury (myocardial injury). You might be able to join if you are 45 or older, have a hip fracture from a minor fall, and show signs of heart muscle injury through a blood test (troponin elevation). The study compares accelerated medical clearance and surgery (aiming for surgery within 6 hours of meeting criteria) to standard care. Researchers want to see if faster surgery reduces deaths within 90 days after joining the study. They will also look at how well people can walk, how quickly they can move around, and other complications, pain, and quality of life.

Study design
This is an international study comparing two groups of participants to see if accelerated surgery is better than standard care. It plans to enroll 1100 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 90 days after joining the study to assess outcomes like mortality and other complications.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04743765

HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial

Recruiting
NAAges 45+InterventionalTreatment
Population Health Research Institute
~1,100 participants
Updated 2026-08-26 on ClinicalTrials.gov
What's tested:Accelerated medical clearance and surgery

At a glance

Recruiting sites
43 of 77 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
All cause mortality
Measured over Within 90 days post randomization
Hip Fractures
Myocardial Injury
77 sites across 52 states
Barcelona7
Ontario5
Italy3
California2
Maryland2
Massachusetts2
Texas2
Wisconsin2
  • Flavia Borges, M.D · PRINCIPAL_INVESTIGATOR · Population Health Research Institute
  • Gerard Slobogean, M.D · PRINCIPAL_INVESTIGATOR · UC Irvine
  • Robert Feibel, M.D · PRINCIPAL_INVESTIGATOR · The Ottawa Hospital
  • PJ Devereaux, M.D · STUDY_CHAIR · Population Health Research Institute

Opens a ready-to-send draft in your own email app — review before sending.

  • All cause mortalityWithin 90 days post randomization

    Death due to all causes